ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

Attendees will obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

ImmunoPrecise Appoints Andy Nixon to Board of Directors

Dr. Nixon brings unique experience and expertise that is directly relevant to IPA.

TetraGenetics and ImmunoPrecise Extend Collaboration for the Discovery of Therapeutic Antibodies

The alliance is focused on the discovery of antibodies against three undisclosed therapeutically-relevant ion-channels.

ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics

Talem is focused on the discovery and development of fully human therapeutic antibodies.

ImmunoPrecise Antibodies Ltd. Trading on OTCQB® Venture Market.

The Company commences trading under the symbol "IPATF".

ImmunoPrecise Launches DeepDisplay™ Antibody Discovery Platform

DeepDisplay™ delivers the most therapeutically-relevant antibodies, in a shorter period of time.

Items 1 to 6 of 65 total

Show per page